Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels

M. Cristine Charlesworth, Charles Y F Young, George G. Klee, Mohammad S. Saedi, Stephen D. Mikolajczyk, Judith A. Finlay, Donald J. Tindall

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objectives. Messenger ribonucleic acid for human glandular kallikrein (hK2), a protein similar to prostate-specific antigen (PSA), is expressed in the prostate. Quantitative tests for the relative amounts of PSA in serum have become important in the diagnosis and management of patients with prostate cancer. Measurement of hK2 in serum may also serve as a diagnostic indicator of disease. The object of this study was to determine if hK2 is present in the serum of patients with high serum concentrations of PSA. Methods. Recombinant prohK2 with an alanine to valine mutation at aa217 (phK2v217) was expressed in a hamster tumor cell line, AV12. The propeptide was treated with trypsin to yield the mature form of hK2 (hK2v217). Using a monoclonal antibody, HK1 G586.1, which recognized wild type and mutant forms of pro- and mature hK2, an hK2-specific radioimmunoassay was developed. Results. PSA cross-reactivity in the radioimmunoassay (RIA) was 0.23%. hK2 was detected in the sera of 51 of 76 patients with PSA levels above 100 ng/m L. The dose-response curve of hK2-positive samples was linear, and recovery of phK2v217-spiked serum samples was close to 100%. The correlation between PSA and hK2 values in the patient sera was low (r = 0.168). Conclusions. Given the importance of the role of PSA as a serologic indicator of prostate cancer, the demonstration that hK2 is also circulating in the blood of patients in different relative proportions to PSA suggests that it may be a significant novel marker for prostate cancer.

Original languageEnglish (US)
Pages (from-to)487-493
Number of pages7
JournalUrology
Volume49
Issue number3
DOIs
StatePublished - May 1997

Fingerprint

Tissue Kallikreins
Prostate-Specific Antigen
Prostate
Serum
Proteins
Prostatic Neoplasms
Radioimmunoassay
Valine
Tumor Cell Line
Cricetinae
Alanine
Trypsin
Monoclonal Antibodies
RNA
Mutation

ASJC Scopus subject areas

  • Urology

Cite this

Charlesworth, M. C., Young, C. Y. F., Klee, G. G., Saedi, M. S., Mikolajczyk, S. D., Finlay, J. A., & Tindall, D. J. (1997). Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology, 49(3), 487-493. https://doi.org/10.1016/S0090-4295(96)00620-6

Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. / Charlesworth, M. Cristine; Young, Charles Y F; Klee, George G.; Saedi, Mohammad S.; Mikolajczyk, Stephen D.; Finlay, Judith A.; Tindall, Donald J.

In: Urology, Vol. 49, No. 3, 05.1997, p. 487-493.

Research output: Contribution to journalArticle

Charlesworth, MC, Young, CYF, Klee, GG, Saedi, MS, Mikolajczyk, SD, Finlay, JA & Tindall, DJ 1997, 'Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels', Urology, vol. 49, no. 3, pp. 487-493. https://doi.org/10.1016/S0090-4295(96)00620-6
Charlesworth, M. Cristine ; Young, Charles Y F ; Klee, George G. ; Saedi, Mohammad S. ; Mikolajczyk, Stephen D. ; Finlay, Judith A. ; Tindall, Donald J. / Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. In: Urology. 1997 ; Vol. 49, No. 3. pp. 487-493.
@article{222963b8b3924779a7fe3402c2bacff8,
title = "Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels",
abstract = "Objectives. Messenger ribonucleic acid for human glandular kallikrein (hK2), a protein similar to prostate-specific antigen (PSA), is expressed in the prostate. Quantitative tests for the relative amounts of PSA in serum have become important in the diagnosis and management of patients with prostate cancer. Measurement of hK2 in serum may also serve as a diagnostic indicator of disease. The object of this study was to determine if hK2 is present in the serum of patients with high serum concentrations of PSA. Methods. Recombinant prohK2 with an alanine to valine mutation at aa217 (phK2v217) was expressed in a hamster tumor cell line, AV12. The propeptide was treated with trypsin to yield the mature form of hK2 (hK2v217). Using a monoclonal antibody, HK1 G586.1, which recognized wild type and mutant forms of pro- and mature hK2, an hK2-specific radioimmunoassay was developed. Results. PSA cross-reactivity in the radioimmunoassay (RIA) was 0.23{\%}. hK2 was detected in the sera of 51 of 76 patients with PSA levels above 100 ng/m L. The dose-response curve of hK2-positive samples was linear, and recovery of phK2v217-spiked serum samples was close to 100{\%}. The correlation between PSA and hK2 values in the patient sera was low (r = 0.168). Conclusions. Given the importance of the role of PSA as a serologic indicator of prostate cancer, the demonstration that hK2 is also circulating in the blood of patients in different relative proportions to PSA suggests that it may be a significant novel marker for prostate cancer.",
author = "Charlesworth, {M. Cristine} and Young, {Charles Y F} and Klee, {George G.} and Saedi, {Mohammad S.} and Mikolajczyk, {Stephen D.} and Finlay, {Judith A.} and Tindall, {Donald J.}",
year = "1997",
month = "5",
doi = "10.1016/S0090-4295(96)00620-6",
language = "English (US)",
volume = "49",
pages = "487--493",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels

AU - Charlesworth, M. Cristine

AU - Young, Charles Y F

AU - Klee, George G.

AU - Saedi, Mohammad S.

AU - Mikolajczyk, Stephen D.

AU - Finlay, Judith A.

AU - Tindall, Donald J.

PY - 1997/5

Y1 - 1997/5

N2 - Objectives. Messenger ribonucleic acid for human glandular kallikrein (hK2), a protein similar to prostate-specific antigen (PSA), is expressed in the prostate. Quantitative tests for the relative amounts of PSA in serum have become important in the diagnosis and management of patients with prostate cancer. Measurement of hK2 in serum may also serve as a diagnostic indicator of disease. The object of this study was to determine if hK2 is present in the serum of patients with high serum concentrations of PSA. Methods. Recombinant prohK2 with an alanine to valine mutation at aa217 (phK2v217) was expressed in a hamster tumor cell line, AV12. The propeptide was treated with trypsin to yield the mature form of hK2 (hK2v217). Using a monoclonal antibody, HK1 G586.1, which recognized wild type and mutant forms of pro- and mature hK2, an hK2-specific radioimmunoassay was developed. Results. PSA cross-reactivity in the radioimmunoassay (RIA) was 0.23%. hK2 was detected in the sera of 51 of 76 patients with PSA levels above 100 ng/m L. The dose-response curve of hK2-positive samples was linear, and recovery of phK2v217-spiked serum samples was close to 100%. The correlation between PSA and hK2 values in the patient sera was low (r = 0.168). Conclusions. Given the importance of the role of PSA as a serologic indicator of prostate cancer, the demonstration that hK2 is also circulating in the blood of patients in different relative proportions to PSA suggests that it may be a significant novel marker for prostate cancer.

AB - Objectives. Messenger ribonucleic acid for human glandular kallikrein (hK2), a protein similar to prostate-specific antigen (PSA), is expressed in the prostate. Quantitative tests for the relative amounts of PSA in serum have become important in the diagnosis and management of patients with prostate cancer. Measurement of hK2 in serum may also serve as a diagnostic indicator of disease. The object of this study was to determine if hK2 is present in the serum of patients with high serum concentrations of PSA. Methods. Recombinant prohK2 with an alanine to valine mutation at aa217 (phK2v217) was expressed in a hamster tumor cell line, AV12. The propeptide was treated with trypsin to yield the mature form of hK2 (hK2v217). Using a monoclonal antibody, HK1 G586.1, which recognized wild type and mutant forms of pro- and mature hK2, an hK2-specific radioimmunoassay was developed. Results. PSA cross-reactivity in the radioimmunoassay (RIA) was 0.23%. hK2 was detected in the sera of 51 of 76 patients with PSA levels above 100 ng/m L. The dose-response curve of hK2-positive samples was linear, and recovery of phK2v217-spiked serum samples was close to 100%. The correlation between PSA and hK2 values in the patient sera was low (r = 0.168). Conclusions. Given the importance of the role of PSA as a serologic indicator of prostate cancer, the demonstration that hK2 is also circulating in the blood of patients in different relative proportions to PSA suggests that it may be a significant novel marker for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0343307126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343307126&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00620-6

DO - 10.1016/S0090-4295(96)00620-6

M3 - Article

C2 - 9123724

AN - SCOPUS:0343307126

VL - 49

SP - 487

EP - 493

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -